Automated system for precise quantification of cell-free DNA in blood samples as part of liquid biopsy analysis. Measures both normal cfDNA and tumor-derived ctDNA to assess cancer burden and genetic changes.
Manufactured by
Biopsense Oy
Jyvaskyla, Finland
BiopSense is developing a fully automated blood processing solution to help health care professionals, such as laboratories to solve the current complicated biopsy workflows with our unique cartridge technology. With the number of treatment options constantly increasing, more frequent monitoring helps the oncologists to respond more quickly in case the treatment is not satisfactory, or a drug resistance is induced. As a result, the patient will receive efficient treatment faster. Cancer medications are often expensive and predicting the effect could be hard, but they can also have the potential to completely cure the cancer. That is why it is important to find the correct medication right as soon as possible. Therefore, screening and constant monitoring for cancer with liquid biopsy is an effective way to improve the quality of cancer treatments and to reduce the burden of cancer. We aim to replace invasive sampling with a less and non-invasive option – liquid biopsy sampling - fully automated.
© 2026 Suplivia · Home · Browse Products